Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi

The in vitro activities of the macrolide antibiotics clarithromycin, 14-hydroxy-clarithromycin, azithromycin, and erythromycin against 19 isolates of Borrelia burgdorferi were investigated. MICs ranged from 0.003 to 0.03 microgram of clarithromycin per ml, 0.007 to 0.03 microgram of 14-hydroxyclarithromycin per ml, 0.003 to 0.03 microgram of azithromycin per ml, and 0.007 to 0.06 microgram of erythromycin per ml. Time-kill studies using the B31 strain of B. burgdorferi demonstrated a > or = 3-log10-unit killing after 72 h with each of the macrolide antibiotics tested in concentrations representing twice the respective MICs.

[1]  M. Vaara Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria , 1993, Antimicrobial Agents and Chemotherapy.

[2]  A. Barbour,et al.  In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies , 1992, Journal of clinical microbiology.

[3]  A. G. Barbour,et al.  Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization , 1992, The Journal of experimental medicine.

[4]  Jerome J. Schentag,et al.  Tissue-directed pharmacokinetics. , 1991, The American journal of medicine.

[5]  S. Malawista,et al.  Lyme disease: recommendations for diagnosis and treatment. , 1991, Annals of internal medicine.

[6]  R. C. Johnson,et al.  Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. , 1989, Reviews of infectious diseases.

[7]  J. Halperin,et al.  A perspective on the treatment of Lyme borreliosis. , 1989, Reviews of infectious diseases.

[8]  K.,et al.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy , 1989, Antimicrobial Agents and Chemotherapy.

[9]  A. Barbour Isolation and cultivation of Lyme disease spirochetes. , 1984, The Yale journal of biology and medicine.

[10]  A. Steere,et al.  Treatment of the early manifestations of Lyme disease. , 1983, Annals of internal medicine.

[11]  P. Thompson,et al.  In vitro inhibition of Borrelia burgdorferi growth by antibodies. , 1993, The Journal of infectious diseases.

[12]  H. Neu The development of macrolides: clarithromycin in perspective. , 1991, The Journal of antimicrobial chemotherapy.

[13]  G. Foulds,et al.  The pharmacokinetics of azithromycin in human serum and tissues. , 1990, The Journal of antimicrobial chemotherapy.